Onconaut Therapeutics
San Diego, United States· Est. 2022
Onconaut Therapeutics is developing cancer drugs that target CHD1L, an oncogene known to drive cancer progression, metastasis, and drug resistance in many cancers including liver, breast, lung, and colon cancers.
Private Company
Funding information not available
About
Onconaut Therapeutics is developing cancer drugs that target CHD1L, an oncogene known to drive cancer progression, metastasis, and drug resistance in many cancers including liver, breast, lung, and colon cancers.
Small Molecules